Longboard Pharmaceuticals, Inc. Stock price

Equities

LBPH

US54300N1037

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
21.6 USD +2.96% Intraday chart for Longboard Pharmaceuticals, Inc. +8.16% +258.21%
Sales 2024 * 2.5M Sales 2025 * - Capitalization 778M
Net income 2024 * -73M Net income 2025 * -104M EV / Sales 2024 * 227 x
Net cash position 2024 * 210M Net cash position 2025 * 263M EV / Sales 2025 * -
P/E ratio 2024 *
-10.3 x
P/E ratio 2025 *
-8.15 x
Employees 50
Yield 2024 *
-
Yield 2025 *
-
Free-Float 75.24%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Longboard Pharmaceuticals, Inc.

1 day+2.96%
1 week+8.16%
Current month-2.61%
1 month-9.77%
3 months+248.39%
6 months+293.44%
Current year+258.21%
More quotes
1 week
19.70
Extreme 19.7
21.81
1 month
18.09
Extreme 18.09
23.29
Current year
16.20
Extreme 16.2
28.15
1 year
3.60
Extreme 3.6
28.15
3 years
2.70
Extreme 2.7
28.15
5 years
2.70
Extreme 2.7
28.15
10 years
2.70
Extreme 2.7
28.15
More quotes
Managers TitleAgeSince
Chief Executive Officer 47 20-01-02
Director of Finance/CFO 50 20-12-31
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Chairman 65 20-11-30
Director/Board Member 68 20-11-30
Director/Board Member 56 20-01-31
More insiders
Date Price Change Volume
24-03-28 21.6 +2.96% 326,906
24-03-27 20.98 +4.33% 354,106
24-03-26 20.11 +1.36% 280,970
24-03-25 19.84 -0.70% 408,319
24-03-22 19.98 +0.05% 398,302

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for neurological diseases. The Company is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). It is focused on developing various product candidates in its pipeline, which includes bexicaserin (LP352) and LP659. The Company plans to advance bexicaserin (LP352), an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no observed impact on 5-HT2B and 5-HT2A receptor subtypes, into a global Phase 3 program. It is also evaluating LP659, an oral, centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, which is in development for the potential treatment of rare neuroinflammatory conditions. The Company is conducting a Phase 1 single-ascending dose (SAD) clinical trial for LP659 in healthy volunteers.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
21.6 USD
Average target price
42.86 USD
Spread / Average Target
+98.41%
Consensus
  1. Stock
  2. Equities
  3. Stock Longboard Pharmaceuticals, Inc. - Nasdaq